单克隆抗体治疗COVID-19的临床和免疫学考虑

S. Bazarova, Z. Saatov, M. Nazirova
{"title":"单克隆抗体治疗COVID-19的临床和免疫学考虑","authors":"S. Bazarova, Z. Saatov, M. Nazirova","doi":"10.48112/acmr.v4i1.47","DOIUrl":null,"url":null,"abstract":"Currently, effective methods for the prevention and treatment of coronavirus infections have not been developed. This could be attributed to the unique pathogenesis of the coronavirus infection and the rapid global spread of the pandemic, which have posed challenges to ongoing research efforts. Similar to other viral infections, coronavirus infection leads to the development and dissemination of the inflammatory process, resulting in viremia or the systemic spread of the infection. This uncontrolled inflammatory response is characterized by elevated levels of cytokines such as IFNy, IL-1, IL-6, and IL-12 in the bloodstream, transitioning the initial inflammatory reaction into a phase known as the cytokine storm. The cytokine storm is marked by severe clinical and laboratory manifestations. Consequently, it is crucial to implement appropriate therapies that target the uncontrolled inflammation induced by the virus rather than viremia itself. Hence, the aim of our study was to investigate the impact of monoclonal antibodies, specifically the medication \"Kazirivimab + Imdevimab,\" which is a combination of recombinant monoclonal antibodies targeting the S-protein, on the clinical progression and laboratory parameters in patients with COVID-19.","PeriodicalId":7266,"journal":{"name":"Advances in Clinical Medical Research and Healthcare Delivery","volume":"50 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical and Immunological Considerations of Monoclonal Antibody Therapy in COVID-19 A Review\",\"authors\":\"S. Bazarova, Z. Saatov, M. Nazirova\",\"doi\":\"10.48112/acmr.v4i1.47\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Currently, effective methods for the prevention and treatment of coronavirus infections have not been developed. This could be attributed to the unique pathogenesis of the coronavirus infection and the rapid global spread of the pandemic, which have posed challenges to ongoing research efforts. Similar to other viral infections, coronavirus infection leads to the development and dissemination of the inflammatory process, resulting in viremia or the systemic spread of the infection. This uncontrolled inflammatory response is characterized by elevated levels of cytokines such as IFNy, IL-1, IL-6, and IL-12 in the bloodstream, transitioning the initial inflammatory reaction into a phase known as the cytokine storm. The cytokine storm is marked by severe clinical and laboratory manifestations. Consequently, it is crucial to implement appropriate therapies that target the uncontrolled inflammation induced by the virus rather than viremia itself. Hence, the aim of our study was to investigate the impact of monoclonal antibodies, specifically the medication \\\"Kazirivimab + Imdevimab,\\\" which is a combination of recombinant monoclonal antibodies targeting the S-protein, on the clinical progression and laboratory parameters in patients with COVID-19.\",\"PeriodicalId\":7266,\"journal\":{\"name\":\"Advances in Clinical Medical Research and Healthcare Delivery\",\"volume\":\"50 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-03-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Clinical Medical Research and Healthcare Delivery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.48112/acmr.v4i1.47\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Clinical Medical Research and Healthcare Delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.48112/acmr.v4i1.47","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目前,还没有有效的预防和治疗冠状病毒感染的方法。这可能是由于冠状病毒感染的独特发病机制和大流行在全球的迅速传播,给正在进行的研究工作带来了挑战。与其他病毒感染类似,冠状病毒感染导致炎症过程的发展和传播,导致病毒血症或感染的全身传播。这种不受控制的炎症反应的特征是血液中IFNy、IL-1、IL-6和IL-12等细胞因子水平升高,将最初的炎症反应转变为称为细胞因子风暴的阶段。细胞因子风暴具有严重的临床和实验室表现。因此,至关重要的是实施适当的治疗,针对由病毒引起的不受控制的炎症,而不是病毒血症本身。因此,我们的研究目的是研究单克隆抗体,特别是针对s蛋白的重组单克隆抗体“Kazirivimab + Imdevimab”组合药物对COVID-19患者临床进展和实验室参数的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Clinical and Immunological Considerations of Monoclonal Antibody Therapy in COVID-19 A Review
Currently, effective methods for the prevention and treatment of coronavirus infections have not been developed. This could be attributed to the unique pathogenesis of the coronavirus infection and the rapid global spread of the pandemic, which have posed challenges to ongoing research efforts. Similar to other viral infections, coronavirus infection leads to the development and dissemination of the inflammatory process, resulting in viremia or the systemic spread of the infection. This uncontrolled inflammatory response is characterized by elevated levels of cytokines such as IFNy, IL-1, IL-6, and IL-12 in the bloodstream, transitioning the initial inflammatory reaction into a phase known as the cytokine storm. The cytokine storm is marked by severe clinical and laboratory manifestations. Consequently, it is crucial to implement appropriate therapies that target the uncontrolled inflammation induced by the virus rather than viremia itself. Hence, the aim of our study was to investigate the impact of monoclonal antibodies, specifically the medication "Kazirivimab + Imdevimab," which is a combination of recombinant monoclonal antibodies targeting the S-protein, on the clinical progression and laboratory parameters in patients with COVID-19.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信